The global oral solid dosage contract manufacturing market is becoming an increasingly important part of the pharmaceutical manufacturing ecosystem as drug developers and pharmaceutical companies turn to specialized contract development and manufacturing organizations (CDMOs) for formulation development, scale-up, and commercial production. Rising outsourcing activity, growing generic drug demand, increasing formulation complexity, and the need for flexible manufacturing capacity are reshaping how oral solid dosage medicines are developed and produced.

The global oral solid dosage contract manufacturing market size was valued at USD 10.2 billion in 2025 and is estimated to reach USD 11.1 billion in 2026. The market is projected to reach USD 21.3 billion by 2033, expanding at a CAGR of 9.7% from 2026 to 2033. North America dominated the market with a 38.7% revenue share in 2025, while Asia Pacific is expected to register the fastest growth during the forecast period. 

Download a free sample copy of the Oral Solid Dosage Contract Manufacturing Market report to understand detailed coverage and inclusions in the final report

Product & Dosage Form Trends

Tablets remain the leading product category in the oral solid dosage contract manufacturing market, accounting for a 32.4% revenue share in 2025. Their widespread pharmaceutical use, established manufacturing processes, cost efficiency, dosing convenience, and scalability continue to support demand from pharmaceutical manufacturers. Capsules represent another important product category and are identified by GVR as the fastest-growing segment during the forecast period. 

The broader product landscape includes tablets, capsules, powders, granules, and other oral solid dosage forms. Increasing formulation requirements are encouraging CDMOs to invest in specialized development capabilities that can accommodate different drug characteristics, production volumes, and release profiles.

The growing complexity of pharmaceutical pipelines is also creating opportunities for manufacturers with advanced formulation and scale-up expertise. Technologies associated with modified-release products, combination therapies, high-potency active pharmaceutical ingredients, and specialized formulations require sophisticated production environments and technical knowledge.

Controlled-Release Technologies & Manufacturing Innovation

Drug-release mechanisms are becoming an important differentiator in the OSD contract manufacturing industry. Controlled release held the largest mechanism share at 52.2% in 2025 and is also identified as the fastest-growing mechanism segment. Controlled-release technologies can help pharmaceutical companies develop dosage forms designed to deliver active ingredients over extended periods, supporting differentiated drug products and specialized therapeutic requirements. 

At the same time, immediate-release and delayed-release products continue to represent important areas of contract manufacturing. GVR identifies immediate release as another significant segment with notable growth during the forecast period. The industry is increasingly adopting automation, process analytical technology, continuous manufacturing, and quality-by-design approaches to improve production consistency, scalability, and regulatory compliance. 

Technological advancements are also expanding the outsourcing opportunity for high-potency oral solid dosage products. Specialized containment systems, advanced API handling capabilities, and stringent occupational-safety requirements can make in-house manufacturing more challenging, encouraging pharmaceutical companies to work with experienced CDMOs.

Outsourcing & Generic Drug Demand

The shift toward outsourcing is one of the primary factors supporting market expansion. Pharmaceutical and biopharmaceutical companies can use CDMOs to reduce capital requirements associated with formulation facilities, manufacturing infrastructure, skilled personnel, and regulatory compliance. Outsourcing also enables companies to access specialized technology and production capacity without building every capability internally. 

The expanding generic drug market provides another important source of demand. Patent expirations create opportunities for generic manufacturers to develop alternative versions of branded medicines, increasing the need for rapid formulation development, scale-up, and high-volume production. CDMOs can provide the manufacturing infrastructure and regulatory expertise required to support these programs.

Demand is also increasing among medium and small-size pharmaceutical and biotechnology companies. The medium and small-size companies segment is expected to register the fastest CAGR during the forecast period, supported by limited internal manufacturing capabilities, high facility investment requirements, and the need to accelerate time-to-market. 

Regional Market Dynamics

North America remained the leading regional market, accounting for 38.7% of global revenue in 2025. Growth in the region is supported by demand for generic medicines, pharmaceutical R&D investment, increasingly complex formulations, and the presence of major CDMOs. The U.S. held the largest country-level market share in 2025. 

Asia Pacific is projected to be the fastest-growing regional market from 2026 to 2033. The region is benefiting from expanding pharmaceutical manufacturing capabilities, increasing outsourcing activity, competitive production environments, and growing demand for medicines. India and China are important markets within the regional OSD contract manufacturing ecosystem. 

Europe, Latin America, and the Middle East and Africa are also included within the global market landscape, with pharmaceutical companies increasingly exploring outsourcing partnerships and localized manufacturing strategies to strengthen supply-chain resilience.

Looking for more specific insights? Customize this report to suite your business needs

Competitive Landscape & Key Companies

The competitive environment includes global CDMOs and specialized pharmaceutical manufacturing companies offering formulation development, manufacturing, scale-up, and commercial production capabilities. Key companies profiled by Grand View Research include Catalent, Inc.; Lonza; Aenova Group; Boehringer Ingelheim International GmbH; Jubilant Pharmova Limited; Patheon Pharma Services; Recipharm AB.; Corden Pharma International; Siegfried Holding AG; Piramal Pharma Solutions; AbbVie Contract Manufacturing; and Next Pharma AB. 

Companies are pursuing acquisitions, collaborations, manufacturing expansions, technology investments, and new service launches to strengthen their market positions. Increasing investments in high-potency manufacturing, continuous processing, digital quality systems, and advanced formulation capabilities are expected to remain important competitive strategies.

Overall, the oral solid dosage contract manufacturing market is being shaped by pharmaceutical outsourcing, generic drug expansion, formulation innovation, and the growing need for flexible and resilient supply chains. With the market expected to increase from USD 11.1 billion in 2026 to USD 21.3 billion by 2033, CDMOs with specialized technologies, scalable manufacturing capacity, strong regulatory expertise, and integrated development-to-commercialization capabilities are positioned to play an increasingly important role in the pharmaceutical supply chain.